Cargando…
Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study
The advent of direct-acting antivirals (DAAs) has transformed the landscape of hepatitis C virus (HCV) management. We aimed to prospectively (real-time) evaluate the feasibility of using a response-guided therapy approach, based on mathematical modeling of early viral kinetics, to reduce the duratio...
Autores principales: | Etzion, Ohad, Dahari, Harel, Yardeni, David, Issachar, Assaf, Nevo-Shor, Anat, Cohen-Naftaly, Michal, Ashur, Yaffa, Uprichard, Susan L., Arbib, Orly Sneh, Munteanu, Daniela, Braun, Marius, Cotler, Scott J., Abufreha, Naim, Keren-Naus, Ayelet, Shemer-Avni, Yonat, Mor, Orna, Murad, Jayanah, Novack, Victor, Shlomai, Amir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575564/ https://www.ncbi.nlm.nih.gov/pubmed/33082372 http://dx.doi.org/10.1038/s41598-020-74568-x |
Ejemplares similares
-
Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease
por: Peleg, Noam, et al.
Publicado: (2018) -
Liver transplant patients infection rate with SARS-CoV-2 is lower but depend upon the infection rate in the general population and have a better outcome
por: Cohen-Naftaly, Michal, et al.
Publicado: (2022) -
Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load
por: Peleg, Noam, et al.
Publicado: (2019) -
Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration
por: Goyal, Ashish, et al.
Publicado: (2022) -
Treatment of chronic hepatitis D with peginterferon lambda—the phase 2 LIMT-1 clinical trial
por: Etzion, Ohad, et al.
Publicado: (2023)